Immunology of term and preterm labor by Peltier, Morgan R
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
Reproductive Biology and 
Endocrinology
Open Access Review
Immunology of term and preterm labor
Morgan R Peltier*
Address: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT 84132, USA
Email: Morgan R Peltier* - mpeltier@hci.utah.edu
* Corresponding author    
Abstract
During pregnancy there is an alteration in maternal immunity within the uterus where innate,
proinflammatory immune responses are tightly regulated to prevent immunological rejection of the
fetal allograft. Disruption of the delicate balance of cytokines by bacteria or other factors increases
the production of proinflammatory cytokines at the maternal-fetal interface and activates the
parturition mechanism prematurely. Despite years of searching, there is still no broadly effective
strategy for preventing preterm labor and most therapies are directed at inhibiting myometrial
contractions and improving neonatal outcome. Recent studies with progestins and interleukin-10
(IL-10), however, are showing promise in randomized clinical trials and animal studies.
Furthermore, the identification of the Toll-like receptors as upstream mediators of inflammation
may offer alternative therapeutic targets for preventing this common pregnancy complication.
Definitions, epidemiology and etiology of 
preterm labor
Preterm labor (PTL) and delivery (PTD) is the foremost
problem in modern obstetrics and is defined as labor or
birth before 37 weeks gestation (relative to the last men-
strual period). Preterm labor is preceded about 30% of the
time by preterm, pre-mature rupture of membranes
(PPROM), which is defined as membrane rupture prior to
37 weeks gestation. In the older literature all babies that
were born less than 2500 g were considered to be prema-
ture. Later studies, using better methods of gestational
dating, however, revealed that many of these infants were
actually delivered at term but were small because of
decreased fetal growth (intrauterine growth restriction –
IUGR). Now that growth curves and detailed statistics
have been established for babies at all gestational ages,
babies that are in the lowest 10th percentile at a given date
of delivery are termed small for gestational age (SGA).
Although the low birth weight (LBW) statistic (born less
that <2500 g without reference to gestational age) does
not distinguish between babies that are SGA or the result
of preterm delivery, it is still used by epidemiologists
because it is easily obtained and useful for populations
that lack access to adequate prenatal care or facilities for
documenting gestational age at birth.
Preterm birth complicated about 11.9% of all pregnancies
in 2001 and the number of babies born preterm has been
steadily increasing for the past two decades [1]. Despite
much effort during the past 40 years, nearly all of the
improvements with treating this pregnancy complication
have been due to advances in neonatology [2,3]. Indeed,
the probability of infant survival for 30 completed weeks
of gestation is >90 % and the limit of fetal survival has
been extended to 24 weeks [4]. The 2 % of babies born
before 32 weeks [1], however, account for about 70 % of
all infant mortality and the infants who do survive are fre-
quently plagued with short and long-term respiratory and
neurological morbidities such as bronchopulmonary dys-
plasia, cerebral palsy, intra-ventricular hemorrhage, pat-
ent ductus arteriosus, and poor school performance in
later years [1,4,5]. Such complications of preterm birth
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consume approximately 10 % of all pediatric health care
costs in the United States and amount to approximately
$5.5–6 billion/year in additional expenditures on health,
education, and childcare [6].
Much of the difficulty in preventing PTL and PTD stems
from the likelihood that PTL is probably the final com-
mon pathway of a number of pregnancy complications
involving the health of the cervix, fetus, fetal membranes,
placenta and myometrium [7]. Known causes of PTL
include: poor nutrition, alcoholism, smoking, infection,
premature rupture of membranes, multiple gestation,
coagulation disorders, and placental abruption [4]. A
common component to many of these conditions, how-
ever, is inflammation at the maternal-fetal interface –
mediated by proinflammatory cytokines. The end result is
that the fetus loses its immunological privileges and is tar-
geted for destruction by the innate immune system. Adap-
tive immunity (caused by classical T-cells) does not seem
to play a significant role in PTL even though a previous
preterm birth is the strongest predictor of a subsequent
preterm birth because gestation length does not decrease
in proportion to number of previous deliveries (as it
would with a classical graft rejection) and many women
have normal pregnancies after a previous preterm birth
[5].
Immunomodulators at the maternal-fetal 
interface
One mechanism by which the fetus maintains its immu-
nological privileges in the uterus is to tightly regulate the
levels of cytokines at the maternal-fetal interface [8].
Although some physiological roles of proinflammatory
cytokines at the maternal-fetal interface have been
described with regard to growth of the placenta and
decidua [9], much of the literature supports the concept
that excessive or aberrant production of proinflammatory
cytokines such as Interleukin (IL)-1β, Tumor necrosis fac-
tor (TNF)-α, and Interferon (IFN)-γ at the maternal-fetal
interface is harmful to pregnancy. IL-10 is also likely to be
an important cytokine because it suppresses the produc-
tion of proinflammatory cytokines by other cells and
numerous studies have documented its production at the
maternal-fetal interface [10-12]. Pregnancy is not depend-
ent upon IL-10 production, however, because IL-10 (-/-)
mice are still fertile [13], suggesting that other immu-
nomodulators may also be contributing to survival of the
fetal allograft.
The best-studied immunomodulator at the maternal-fetal
interface is progesterone (P4), which clearly has a role in
survival of the fetal allograft [14]. Numerous experiments
have demonstrated that progesterone blocks mitogen-
stimulated lymphocyte proliferation, improves allograft
survival time, modulates antibody production, decreases
the oxidative burst of monocytes, reduces the production
of proinflammatory cytokines by macrophages in
response to bacterial products and alters cytokine secre-
tion of T-cell clones to favor IL-10 production [15-17].
The mechanism by which progesterone exerts its immu-
nomodulatory actions in reproductive tissues is unclear
but may involve both direct and indirect actions on
immune cells. The concentrations of progesterone that are
needed to inhibit lymphocyte proliferation in vitro are
well above the KD for its receptors and cannot be blocked
by RU486 [18], suggesting that the effects are mediated
through a different type of receptor such as the glucocor-
ticoid receptor. The concentrations of progesterone at the
maternal-fetal interface at late pregnancy are in the range
of 1–5 µg/mg protein [19]. Therefore, such direct effects of
progesterone on immune function described in these in
vitro experiments are physiological. Proteins with immu-
nosuppressive activities that are produced under the influ-
ence of progesterone have been described for the
ruminant endometrium and human leukocytes (reviewed
in [20] and [21]). Such proteins may alter the prolifera-
tion, activation and effector functions of immune cells at
the maternal-fetal interface and may provide an alterna-
tive, indirect mechanism for P4-mediated
immunosuppression.
Immunomodulators during parturition
The process of labor involves three physiologically inter-
dependent processes: remodeling of cervix to allow it to
stretch open to the width of the reproductive tract, weak-
ening and rupture of the membranes in the region that
overlies the cervix and the initiation of rhythmic contrac-
tions of increasing amplitude and frequency that ulti-
mately forces the fetus and placenta from the dam. Some
of these processes seem to be mediated by the proinflam-
matory cytokines, suggesting that the immune privileges
that the fetal-placental unit has enjoyed during pregnancy
are revoked at the time of labor. An inflammatory
response during labor may also help to remove placental
fragments and prepare the uterus for the pathogens that it
will undoubtedly encounter during the immediate post-
partum period.
Role of progesterone in parturition
In rodent and ruminant models of pregnancy, labor is pre-
ceded by a rapid decline in peripheral P4 concentrations
[22]. In primates and guinea pigs, however, P4 concentra-
tions remain elevated until the delivery of the placenta
[23,24]. However, blockade of progesterone receptors
with RU486 is a very efficient way to stimulate labor in
primates [25-27]. This suggests that removal of progester-
one causes labor but that this mechanism may not be
required for initiating parturition. This discrepancy in the
parturition mechanism of primates and rodents but the
conserved production of estradiol at term acrossReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/122
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mammalian species has led to the hypothesis that the
estrogen:progesterone ratio is more important at term
than absolute levels of these hormones and that increased
estradiol abrogates the biological effects of progesterone.
Recent studies have suggested that there may be a "func-
tional withdrawal" of P4 in a number of gestational tissues
in primates by modulation of progesterone receptors. The
P4 receptor has been found to be important to suppressing
the inflammatory properties of estradiol in mice [28].
Blockade or abrogation of the function of P4 receptors
could permit proinflammatory cascades to occur in utero
at term in conjunction with rising estradiol levels. In the
decidua there is a significant loss in P4 receptor binding to
its response element in samples collected after labor [29].
During labor, there is a significant shift of P4 receptor
types in the myometrium from the B-form to the A-form
and there was significantly less expression of both recep-
tors on the amnion [30]. The A-form of the P4 receptor
appears to inhibit signal transduction of the B-form
because myometrial cells that were transfected with both
receptors failed to initiate gene expression, whereas those
transfected with the B-form only did [31]. In human cer-
vical stroma, a shift from B-form to A-form of the P4 recep-
tor with no total change in P4 receptors has also been
described [32].
Immunological changes in the cervix during parturition
With the influence of P4 abrogated, IL-8, IL-1β, IL-6 and
TNF-α production increases in the human cervix during
cervical ripening and labor [33-35]. Immunohistochemi-
cal analyses of cervical biopsies have shown that IL-1β is
produced predominantly by leukocytes, IL-6 by leuko-
cytes, glandular epithelial cells and surface epithelial cells,
and IL-8 is produced primarily by leukocytes, glandular
epithelial cells, surface epithelial cells and stromal cells
[36]. During labor there is an influx in the number of leu-
kocytes in the cervix that is caused primarily by increased
numbers of neutrophils (neutrophil elastase+ cells) and
macrophages (CD68+ cells) but not T (CD3+ cells) or B-
cells (CD20+ cells) [33].
Proinflammatory cytokines can induce the ripening of the
cervix in a number of ways. IL-1β and TNF-α increases the
production of matrix metalloproteinase (MMP)-1, MMP-
3, MMP-9, and cathepsin S [37]. Furthermore, IL-1β
downregulates the expression of tissue inhibitor of metal-
loproteinase (TIMP)-2, an endogenous inhibitor of MMP-
2 [37]. Such proteinases can digest the collagen and elas-
tin fibers in the extracellular matrix of the cervix to further
increase cervical compliance. IL-1β can act on a number of
cell types to increase the production of cyclooxygenase
(COX)-2 and prostaglandin E2 (PGE2), the most effective
chemical for inducing cervical dilation in women. IL-1α,
which uses the same receptor as IL-1β, has been shown
experimentally to increase COX-2 and PGE2 production
by rabbit cervical smooth muscle cells [38]. Prostaglandin
E2 may then further stimulate labor by increasing the pro-
duction of proteinases or may play an indirect role, by
increasing the permeability of blood vessels for leukocyte
trafficking [39]. Nitric oxide (NO), another proinflamma-
tory mediator that is increased at term, may also contrib-
ute to vasodilation in order to facilitate leukocyte
trafficking [39].
IL-8 causes neutrophils from the periphery to migrate
towards the cervix and can activate them to release MMP-
8 (neutrophil collagenase) and neutrophil elastase that
can digest the extracellular matrix produced by cervical
fibroblasts. Increased concentrations of granulocyte-CSF
(G-CSF) in the cervix during labor may also stimulate pro-
liferation of the neutrophil subset [40]. The role of IL-6 in
the cervix during labor is unclear in normal pregnancy but
this cytokine has been used as an effective biomarker for
predicting labor. Possible roles could be to stimulate neu-
trophils, macrophages or other cells in the local tissues to
produce additional proinflammatory cytokines that aid
the process of cervical ripening such as PGE2 or NO.
Immunological changes in the membranes during 
parturition
In the membranes, a similar proinflammatory process
takes place as described above in the cervix. During labor,
the production of IL-8, TNF-α, IL-6 and IL-1β increases in
membranes [36,41]. Also there are increased amounts of
MMP-9 [42-44] but not MMP-2 [44] and decreased levels
of the TIMPs [45]. A promoter polymorphism of the
MMP-9 gene that is associated with increased production
of this enzyme is associated with increased risk for
PPROM in African-Americans [46]. TNF-α and IL-1β
increase the production of MMP-9 by amnion, but not
chorion, explants in vitro [47]. Intra-amniotic infusion of
IL-1β into catheterized rhesus monkeys increases the
activity of MMP-9 but not MMP-2 [48]. Increased colla-
genase activity can then weaken the tensile strength of the
membranes and lower their threshold for rupture.
Proinflammatory cytokines can also increase the produc-
tion of prostaglandins in the membranes. Stimulation of
amnion and chorion cells with IL-1β and TNF-α also
increases the production of PGE2 [49-51] via COX-2 [52].
PGE2  may then either cause increased production of
MMP-9 [53] or it could cross the membranes to stimulate
cervical ripening in the cervix or stimulate contractions by
the myometrium. Although the amnion produces signifi-
cant quantities of PGE2 during pregnancy, there is little
effect of this hormone on the uterus or cervix because the
chorion and trophoblast produce an enzyme, 15-hydrox-
yprostaglandin dehydrogenase (PGDH), which converts
PGE2 and PGF2α to inactive metabolites. Hormones andReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/122
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cytokines associated with labor such as cortisol, TNF-α
and IL-1β have been shown to inhibit the production of
PGDH [54-56], which may contribute to increased pros-
taglandin production during labor.
Immunological changes in the myometrium during 
parturition
The pattern of cytokine-induced changes described above
also seems to occur in the myometrium where increased
protein and/or mRNA concentrations of IL-1β, TNF-α and
IL-6 are associated with labor [33,36]. These proinflam-
matory cytokines have been immunolocalized to the leu-
kocytes in the myometrium, which are increased during
labor [36]. The increased concentrations of leukocytes in
the myometrium during labor could be due to increased
expression of chemokines such as MCP-1 and IL-8 that are
also increased during labor [33,36,57,58] and may recruit
macrophages and neutrophils to the myometrium. IL-1β
and TNF-α stimulate arachidonic acid release, activate
phospholipid metabolism [59] and increase the produc-
tion of prostaglandins by the myometrium [60,61]. IL-1β
activates a signal transduction system involving NF-κB to
increase the expression of COX-2 [62], which is increased
in the myometrium during labor [63,64], and stimulates
the production of PGE2 by myometrial cells [65]. These
effects of IL-1β on myometrial cells are similar to the
effects of oxytocin which also upregulates COX-2 and
PGE2 production by myometrial cells [66]. Oxytocin and
PGE2 both increase intracellular calcium concentrations
in myometrial cells, which is required for uterine contrac-
tions [67].
Although IL-6 has no effect on prostaglandin production
by myometrial cells [65] and is unable to stimulate myo-
metrial contractions [68], this cytokine may play a role in
labor by increasing the expression of oxytocin receptors
on myometrial cells [69] to increase their responsiveness
to oxytocin. Like IL-1β, IL-6 can also increase oxytocin
secretion by myometrial cells [70]. IL-1β and TNF-α can
also increase the production of MMP-9 by myometrial
cells, which may be important for detachment of the pla-
centa [71].
Infection and inflammation as a cause of 
preterm labor
Infection is the most frequent cause of PPROM and PTL
and is clearly identifiable in over 30% of cases. The organ-
isms most commonly associated with PTL include: Urea-
plasma urealyticum,  Mycoplasma hominis,  Streptococcus
agalactae, and Escherichia coli [72,73]. Koch's postulates
for these organisms as pathogens in PTL have been ful-
filled in number of studies using primate, rabbit or rodent
models of pregnancy [74-79]. Clinical studies have also
demonstrated that intra-amniotic infection is associated
with PTL, PPROM and other adverse pregnancy outcomes
[80-82].
Infection may cause PPROM and PTL by causing a prema-
ture activation of cytokine cascades that in turn, activate
the parturition mechanisms described above. Amniotic
fluid concentrations for a large number of proinflamma-
tory mediators such as IL-1β, TNF-α, IL-6, MMP-9, and IL-
8 have been compared between women with intra-amni-
otic infection and those with sterile amniotic fluids. The
overwhelming majority of these studies suggest that pro-
duction of these and other proinflammatory cytokines is
increased during intra-amniotic infection, PTL or PPROM
[83-97]. Similar studies conducted using samples col-
lected from other gestational tissues (i.e. cervical/vaginal
fluid, placenta or membranes) [34,35,91,98-102] also
support the concept that premature activation of
cytokines by infectious organisms may result in PTL or
PPROM.
Administration of bacteria or bacterial products to
rodents or primates during late pregnancy causes PTL that
is preceded by increased production of proinflammatory
cytokines including TNF-α and IL-1β [74,103-105].
Administration of IL-1β was able to mimic the effects of
bacteria by causing PTL, suggesting a causal role for this
cytokine in infection-induced PTL [106,107]. TNF-α did
not cause preterm birth but did cause intrauterine fetal
death [104]. The source of these cytokines is unclear but
may originate from trophoblast cells as well as fetal or
maternal macrophages. Cultures of amnion, chorion, and
decidual cells produce proinflammatory cytokines in
response to bacteria or bacterial products [108-111]. It is
also possible that macrophage-derived cytokines can act
on receptors on placental cells, which, in turn, augment
the production of proinflammatory cytokines at the
maternal-fetal interface.
Downstream effects of proinflammatory cytokines likely
include: increased production of free radicals such as NO,
increased prostaglandin production, and increased pla-
cental apoptosis. Increased concentrations of NO and
PGE2 in amniotic fluid are associated with intrauterine
infection [88,112]. Both COX-2 and iNOS are upregu-
lated in murine gestational tissues in response to LPS
[113]. Furthermore, inhibitors of cyclooxygenases and
nitric oxide synthases (iNOS) block LPS-induced PTL in
mice [114-116].
Host-pathogen interactions that may result in 
inflammation at the maternal-fetal interface
How pathogens interact with immune cells to stimulate
inflammatory processes in the reproductive tract is poorly
understood. Recent advances in developmental biology
and functional genomics, however, has led to theReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/122
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discovery of a family of receptors, the toll-like receptors
(TLRs), that have intracellular domains with high homol-
ogy to the IL-1 receptor. These proteins are expressed on
the surface of many immune and non-immune cells and
the extracellular domains of these proteins function as
molecular sentinels for biomolecules on different classes
of pathogens. For example, TLR-2 recognizes di- and tri-
palmitoylated peptides, TLR-4 recognizes the lipid A com-
ponent of LPS. TLR-3 recognizes double stranded RNA
which may be released by virus infected cells. TLR-5 recog-
nizes flagellar proteins from pilliated E. coli and yeast
cells. TLR-9 enables immune cells to respond to CpG
DNA, which is more common in bacteria [117]. Data are
conflicting on the recognition of lipoteichoic acid that is
produced by Gram-positive organisms with some studies
implicating a role for TLR-2 [118] and others a role for
TLR-4 [119] for its effects on cells. TLR-1 and TLR-6 dimer-
ize with TLR-2 to detect fine differences in molecular
structure with TLR-6 enabling the detection of dipalmi-
toylated lipids such as MALP-2 from Mycoplasma [120]
and TLR-1 enabling the detection of tripalmitoylated lip-
ids such as those from Borrellia [121]. The functions of the
other TLRs are unknown, but they may serve some acces-
sory functions or they may recognize other, undiscovered,
mediators of inflammation.
In addition to detecting pathogens, the TLRs also may
play a role in responding to endogenous mediators of tis-
sue damage or injury. TLR-4 can be activated by stress-
induced fibronectin that carries the extra domain A [122]
to increase the production of MMP-9 by THP-1 cells. Sur-
factant protein A has a similar effect on THP-1 cells but
this is mediated via TLR-2 [123]. Heat Shock Protein-70
(hsp 70), gp96 and hsp 60 increase the production of
proinflammatory cytokines through both TLR-2 and TLR-
4 [124-127]. Extravascular fibrinogen may also modulate
chemokine production by macrophages via TLR-4 [128].
The ability for cells to respond to endogenous mediators
of inflammation is consistent with the "Danger" model of
immunity. This model predicts that immunity is not due
merely to the foreignness of antigens but also for their
capacity to do damage and is based on numerous obser-
vations that tissue injury or necrosis is associated with
greater immune responses (such as the need for adjuvants
to get an effective immune response) [129].
Toll-like receptors appear to be a missing link between
innate and adaptive immunity because the different
receptors bind ligands that are more prevalent on differ-
ent classes of pathogens and may be able to direct adap-
tive immunity to respond to a particular group pathogens.
Recent studies have shown that TLR-2 and TLR-9 agonists
stimulate a subset of the genes that are normally induced
by TLR-4 [130-132]. For example, the proinflammatory
cytokines and chemokines IL-1β, MIP-1α, MIP-2, IL-6,
TNF-α and IFN-γ are induced by murine macrophages in
response to both TLR-2 and TLR-4 agonists, however,
iNOS, IL-12p40, IP-10 and MCP-5 are produced primarily
in response to TLR-4 agonists [130,131]. In human den-
dritic cells, TLR-2 agonists more efficiently increased pro-
duction of IL-8 and IL-23 than did TLR-4 agonists [133].
One of the genes that is induced by TLR-4 but not TLR-2
agonists is IFN-β that functions as a pivotal factor between
array of genes produced by TLR-2 and TLR-4 agonists
[131]. Stimulation of macrophages with TLR-2 agonists
and IFN-β results in a cytokine pattern that is similar to
that induced by TLR-4 ligands [131].
How the TLRs mediate inflammation at the maternal-fetal
interface is only beginning to be studied. A better under-
standing of these proteins and the signal transduction cas-
cades that they mediate may explain why some
pregnancies are complicated by PTL and PPROM whereas
others are only affected by PPROM. More investigations
into the endogenous activators of the TLRs may also
explain how PTL and PPROM can occur in the absence of
infection (e.g. preeclampsia, multiple gestation, teenage
pregnancy, or due to excessive tobbacco and alcohol con-
sumption). These molecules may be excellent targets for
therapeutic strategies because they are upstream media-
tors of the proinflammatory cascade that ultimately
results in PTL.
Messenger RNA for all of the TLRs is present in the human
placenta [134] and studies on pregnant mice have
revealed that expression of TLR-2 and TLR-4 is present
throughout the second half of pregnancy [135]. The
human term placenta also expresses TLR-2 and TLR-4 in
the syncytiotrophoblast, which would be in direct contact
with invading pathogens [136]. Although the levels of
TLR-2 and TLR-4 expression did not increase in the
human placenta during labor or in response to TNF-α,
these receptors do seem to be functional because IL-8 and
TNF-α secretion by placental explants was increased after
incubation with zymosan (a TLR-2 agonist) or LPS (a TLR-
4 agonist) [136]. One genetic polymorphism for TLR-4,
Asp299Gly, results in decreased receptor function and was
associated with a pre-disposition to PTL in a Finnish pop-
ulation [137]. This result is surprising, because C3H/HeJ
mice, which that lack a functional TLR4, are resistant to
PTL induced by E. coli [138,139].
New immunomodulatory treatments for 
preterm labor
Classical strategies for treating and preventing PTL have
focused on blocking the myometrial contractions with β-
mimetics, oxytocin antagonists, cyclooxygenase inhibi-
tors and magnesium sulfate. Although there are many
clinical studies evaluating these treatments, the results are
conflicting, suggesting that no single tocolytic treatmentReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/122
Page 6 of 11
(page number not for citation purposes)
may be effective for all women in PTL. Furthermore, there
can be significant risks with some of these treatments
including cardiac problems and patent ductus arteriosus.
Using the assumption that most PTL is caused by intrau-
terine infection, a number of randomized clinical trials
have been conducted to determine if antibiotics can
improve pregnancy outcome. These trials have yielded
conflicting results due to differences in inclusion criteria,
study design, organism studied and the static vs. cidal
activity of many antibiotics.
Model for biochemical cascades involved with preterm labor Figure 1
Model for biochemical cascades involved with preterm labor. Toll-like receptors recognize conserved bacterial motifs or pro-
teins that are indicative of cellular damage to increase the production of arrays of proinflammatory cytokines that may differ 
between TLRs. These cytokines and chemokines can increase one another to augment their production, recruit neutrophils 
(NΦ) and macrophages (MΦ) to the maternal-fetal interfaces, and increase the production of downstream mediators of inflam-
mation- the most important of which seem to be prostaglandins and matrix metalloproteinases. These downstream mediators 
have varying effects in different tissues. In the myometrium, prostaglandins contribute to increased uterine contractions and 
matrix metalloproteinases may contribute to detachment of the placenta. In the cervix, these mediators cause degradation of 
the extracellular matrix resulting in effacement and dilation. Increased activity of matrix metalloproteinases in the membranes 
reduces the pressure required for membrane rupture. During much of pregnancy, immunosuppressive substances such as pro-
gesterone (P4) and IL-10 suppress these proinflammatory cascades and downstream regulators such as the TIMPs and PGDH 
may also play a role in prolonging pregnancy. Current literature suggests that excessive levels of stress proteins or infectious 
organisms may override the protective effects of such molecules to cause preterm labor and/or PPROM.
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Due to the correlative role of inflammation in PTL, some
of the newer strategies being investigated are focused on
the antiinflammatory effects of IL-10 and progesterone.
Administration of LPS to pregnant rats between gestation
day 14 and 17 causes extensive intrauterine growth retar-
dation, fetal death and low birth weight [140]. This is
associated with increased production of TNF-α and NO in
the placenta and increased numbers of apoptotic cells
[140]. Co-administration of IL-10 to LPS-treated dams
improved fetal outcome by restoring birth weight, increas-
ing liter size and decreasing placental TNF-α, NO and
apoptosis [140]. Intravenous administration of IL-10 also
prevents preterm birth caused by intrauterine infusion of
LPS in rats [141]. IL-10 also decreased the production of
proinflammatory cytokines in the brains of pups born to
dams that received 107 CFU E. coli via intrauterine injec-
tion during pregnancy [142]. Increased production of
proinflammatory cytokines in fetal or neonatal brains is
associated with periventricular leukomalacia, a major risk
factor for cerebral palsy [143]. These results suggest that
IL-10 may be helpful in reducing the incidence of PTL and
the resulting neonatal morbidity.
IL-10 may function by decreasing LPS-stimulated IL-1β
that could prevent the induction of COX-2 and ultimately
lead to decreased PGE2 in the gestational tissues [144].
Alternatively, IL-10 may increase the catabolism of pros-
taglandins by the membranes. IL-10 blocked the TNF-α
and IL-1β-induced decreases in chorion PGDH expression
[56]. Furthermore, IL-10 blocked IL-1β-induced PTL in
rhesus monkeys, indicating that IL-10 may function at
steps downstream from IL-1β in vivo [145].
Progestins have also been shown to be effective in pre-
venting PTL and delivery. Administration of pharmaco-
logical, but not physiological levels, of progesterone to
mice delayed PTL in response to intrauterine injection of
E. coli [146]. In women with a history of preterm birth, the
synthetic progestin, 17α-OH progesterone-caproate sig-
nificantly reduced the rate of delivery at 30, 32, or 37
weeks gestation [147]. Although the results were highly
significant, this study is complicated by an unusually high
rate of repeat PTD in the control group (>50%), suggest-
ing that the effect may be limited to only a subset of
women who succumb to PTL. A similar study, however,
demonstrated that 100 mg P4 via vaginal suppositories
administered daily significantly lowered the rate of PTL
(to 13.8 %) and was characterized by a more reasonable
rate of PTL in the placebo group (28.5 %) [148]. Proges-
terone, however, should be given cautiously to women
because animal studies have indicated that progesterone
makes the uterus more susceptible to bacterial infection
[149,150]. Widespread P4 treatment without simultane-
ous prophylactic antibiotic therapies could lead to
increased growth of bacteria in the uterus and cause more
infants to be born with bacterial sepsis. Neither of the
studies referenced above were designed to have had suffi-
cient power to detect a reduction in most measurements
of perinatal morbidity and mortality and meta-analyses of
previous studies demonstrated no improvement in neo-
natal outcome for women who received 17α-hydroxypro-
gesterone caproate [151]. However, decreased relative risk
for intraventricular hemorrhage and requirement for sup-
plemental oxygen was observed in the study by the net-
work of maternal-fetal medicine units [147].
Nevertheless, these studies have led to a flurry of research
that is now underway to determine if progestin supple-
mentation is effective in women with multiple gestations,
and whether other routes of administration and other
types of synthetic progestins are effective. Hopefully these
new treatments either, alone or combined with other ther-
apies, will reduce the huge burden of infant morbidity
and mortality caused by PTL and PPROM that is placed on
families and society.
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